Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
22.11
-0.81 (-3.53%)
Dec 5, 2025, 4:00 PM EST - Market closed
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| EMEA Revenue | 692.77M | 667.83M |
Log In |
Log In |
Log In | Upgrade
|
| APAC Revenue | 101.03M | 96.24M |
Log In |
Log In |
Log In | Upgrade
|
| North America Revenue | 321.83M | 308.95M |
Log In |
Log In |
Log In | Upgrade
|
| South America Revenue | 29.47M | 31.02M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | 1,000.00 | 1,000.00 |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 1.15B | 1.10B |
Log In |
Log In |
Log In | Upgrade
|
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Biopharmaceutical and Diagnostic Solutions Revenue | 976.82M | 933.74M |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Revenue | 168.28M | 170.29M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 1.15B | 1.10B |
Log In |
Log In |
Log In | Upgrade
|
Gross Profit
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Biopharmaceutical and Diagnostic Solutions Gross Profit | 298.47M | 268.78M |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Gross Profit | 47.14M | 56.17M |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Gross Profit | -24.54M | -22.63M |
Log In |
Log In |
Log In | Upgrade
|
| Gross Profit (Other) | 1,000.00 | - |
Log In |
Log In |
Log In | Upgrade
|
| Gross Profit (Total) | 321.08M | 302.32M |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Biopharmaceutical and Diagnostic Solutions Operating Profit | 193.51M | 165.64M |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Operating Profit | 28.95M | 33.10M |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Operating Profit | -38.58M | -37.59M |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 183.88M | 161.14M |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 |
| Backlog | 853.00M |
Log In |
Log In |
Log In | Upgrade
|